RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
CSPC Pharmaceutical Group Stock

CSPC Pharmaceutical Group EBIT 2024

CSPC Pharmaceutical Group EBIT

8.29 B CNY

Ticker

1093.HK

ISIN

HK1093012172

WKN

548183

In 2024, CSPC Pharmaceutical Group's EBIT was 8.29 B CNY, a 12.82% increase from the 7.35 B CNY EBIT recorded in the previous year.

The CSPC Pharmaceutical Group EBIT history

YEAREBIT (undefined CNY)
2029e-
2028e7.4
2027e7.12
2026e9.71
2025e9.06
2024e8.29
20237.35
20227.19
20216.5
20205.56
20194.65
20183.73
20173.14
20162.38
20151.81
20141.5
20130.95
20120.61
20110.31
20100.95
20091.04
20081.09
20070.67
20060.1
20050.23
20040.29

CSPC Pharmaceutical Group Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into CSPC Pharmaceutical Group, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by CSPC Pharmaceutical Group from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects CSPC Pharmaceutical Group’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of CSPC Pharmaceutical Group. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into CSPC Pharmaceutical Group’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing CSPC Pharmaceutical Group’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on CSPC Pharmaceutical Group’s growth potential.

CSPC Pharmaceutical Group Revenue, EBIT and net profit per share

DateCSPC Pharmaceutical Group RevenueCSPC Pharmaceutical Group EBITCSPC Pharmaceutical Group Net Income
2029e38.36 B undefined0 undefined6.33 B undefined
2028e36.93 B undefined7.4 B undefined6.21 B undefined
2027e35.37 B undefined7.12 B undefined5.98 B undefined
2026e37.69 B undefined9.71 B undefined7.97 B undefined
2025e35.37 B undefined9.06 B undefined7.27 B undefined
2024e33.47 B undefined8.29 B undefined6.63 B undefined
202331.45 B undefined7.35 B undefined5.87 B undefined
202230.94 B undefined7.19 B undefined6.09 B undefined
202127.87 B undefined6.5 B undefined5.61 B undefined
202024.94 B undefined5.56 B undefined5.16 B undefined
201922.1 B undefined4.65 B undefined3.71 B undefined
201817.72 B undefined3.73 B undefined3.08 B undefined
201713.85 B undefined3.14 B undefined2.48 B undefined
201611.08 B undefined2.38 B undefined1.88 B undefined
20159.5 B undefined1.81 B undefined1.39 B undefined
20149.84 B undefined1.5 B undefined1.14 B undefined
20137.89 B undefined948 M undefined771 M undefined
20123.37 B undefined613 M undefined1.76 B undefined
20116.13 B undefined312 M undefined194 M undefined
20106.77 B undefined950 M undefined655 M undefined
20096.2 B undefined1.04 B undefined855 M undefined
20086.1 B undefined1.09 B undefined839 M undefined
20074.86 B undefined669 M undefined465 M undefined
20063.63 B undefined103 M undefined16 M undefined
20053.36 B undefined230 M undefined165 M undefined
20042.6 B undefined290 M undefined260 M undefined

CSPC Pharmaceutical Group stock margins

The CSPC Pharmaceutical Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of CSPC Pharmaceutical Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for CSPC Pharmaceutical Group.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the CSPC Pharmaceutical Group's sales revenue. A higher gross margin percentage indicates that the CSPC Pharmaceutical Group retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the CSPC Pharmaceutical Group's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the CSPC Pharmaceutical Group's total revenue generated. When comparing the revenue margin year over year, investors can gauge the CSPC Pharmaceutical Group's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the CSPC Pharmaceutical Group. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the CSPC Pharmaceutical Group's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

CSPC Pharmaceutical Group Margin History

CSPC Pharmaceutical Group Gross marginCSPC Pharmaceutical Group Profit marginCSPC Pharmaceutical Group EBIT marginCSPC Pharmaceutical Group Profit margin
2029e70.51 %0 %16.51 %
2028e70.51 %20.03 %16.81 %
2027e70.51 %20.12 %16.9 %
2026e70.51 %25.76 %21.16 %
2025e70.51 %25.63 %20.55 %
2024e70.51 %24.77 %19.8 %
202370.51 %23.37 %18.68 %
202271.94 %23.25 %19.69 %
202175.84 %23.34 %20.11 %
202074.91 %22.3 %20.69 %
201971.98 %21.03 %16.8 %
201866.25 %21.03 %17.39 %
201760.44 %22.65 %17.92 %
201651 %21.48 %16.98 %
201545.82 %19 %14.62 %
201438.22 %15.25 %11.58 %
201331.49 %12.02 %9.78 %
201243.53 %18.18 %52.16 %
201120.08 %5.09 %3.17 %
201029.24 %14.02 %9.67 %
200932.25 %16.82 %13.8 %
200833.4 %17.83 %13.76 %
200730.82 %13.77 %9.57 %
200617.32 %2.84 %0.44 %
200521.72 %6.84 %4.91 %
200425.73 %11.14 %9.98 %

CSPC Pharmaceutical Group Aktienanalyse

What does CSPC Pharmaceutical Group do?

CSPC Pharmaceutical Group Ltd. is a leading pharmaceutical company in China. It was founded in 1997 and specializes in the manufacturing of pharmaceutical raw materials, intermediates, and finished drugs. The company's product range covers various therapy areas and provides a variety of medications for patients worldwide. The company's business model is based on research, development, and production of pharmaceutical products for the mass market. In 2019, CSPC Pharmaceutical achieved a revenue of 9.9 billion USD. The company's products are represented in 24 countries worldwide and aim to improve people's lives through innovations in the healthcare sector. CSPC Pharmaceutical has various divisions, including its sister company CSPC Zhongqi Pharmaceutical Technology Co. Ltd., which specializes in innovative technologies for drug manufacturing. Other divisions include CSPC Weisheng Pharmaceutical Co. Ltd. for marketing and distribution in China, as well as CSPC Ouyi Pharmaceutical Co. Ltd. for the production of traditional Chinese medicines. The product range of CSPC Pharmaceutical is diverse and offers medications for various application areas. This includes cancer therapy with products such as Anastrozole tablets and Vinorelbine injection solution. In the field of cardiovascular diseases, CSPC Pharmaceutical offers Metoprolol Succinate tablets. Additionally, the company provides products for the treatment of pain and inflammation, such as Ibuprofen suspension and generic versions of Celecoxib. Another focus of the company is the research and production of antibiotics, which are important medications in the treatment of bacterial infections. CSPC Pharmaceutical produces a wide range of antibiotics in different dosage forms, including Cefazolin Sodium injection solutions and Cefalotin Sodium injection solutions. Throughout its history, CSPC Pharmaceutical has received various awards and certifications that confirm the high quality of its products. In 2019, the company was honored as the "Best Innovative Pharmaceutical Firm" at the Asia-Pacific Biotech Industry Awards. Furthermore, CSPC Pharmaceutical has obtained the ISO 9001:2015 Quality Management System certificate, and its products are approved by the US FDA, the European Medicines Agency, and the National Medical Products Administration in China. Overall, CSPC Pharmaceutical is an important player in the Chinese pharmaceutical market, offering a wide product range and increasing the level of innovation through research and development. With its continuous growth and efforts towards quality and innovation, CSPC Pharmaceutical will continue to play a significant role in the global healthcare market. CSPC Pharmaceutical Group ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing CSPC Pharmaceutical Group's EBIT

CSPC Pharmaceutical Group's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of CSPC Pharmaceutical Group's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

CSPC Pharmaceutical Group's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in CSPC Pharmaceutical Group’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about CSPC Pharmaceutical Group stock

How much did CSPC Pharmaceutical Group achieve in EBIT for the current year?

In the current year, CSPC Pharmaceutical Group has achieved an EBIT of 8.29 B CNY.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company CSPC Pharmaceutical Group.

How has the EBIT of CSPC Pharmaceutical Group developed in recent years?

The EBIT of CSPC Pharmaceutical Group has increased by 12.825% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company CSPC Pharmaceutical Group?

The EBIT of CSPC Pharmaceutical Group is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does CSPC Pharmaceutical Group pay?

Over the past 12 months, CSPC Pharmaceutical Group paid a dividend of 0.25 CNY . This corresponds to a dividend yield of about 4.58 %. For the coming 12 months, CSPC Pharmaceutical Group is expected to pay a dividend of 0.28 CNY.

What is the dividend yield of CSPC Pharmaceutical Group?

The current dividend yield of CSPC Pharmaceutical Group is 4.58 %.

When does CSPC Pharmaceutical Group pay dividends?

CSPC Pharmaceutical Group pays a quarterly dividend. This is distributed in the months of October, June, July, November.

How secure is the dividend of CSPC Pharmaceutical Group?

CSPC Pharmaceutical Group paid dividends every year for the past 17 years.

What is the dividend of CSPC Pharmaceutical Group?

For the upcoming 12 months, dividends amounting to 0.28 CNY are expected. This corresponds to a dividend yield of 5.15 %.

In which sector is CSPC Pharmaceutical Group located?

CSPC Pharmaceutical Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von CSPC Pharmaceutical Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of CSPC Pharmaceutical Group from 11/20/2024 amounting to 0.16 CNY, you needed to have the stock in your portfolio before the ex-date on 10/31/2024.

When did CSPC Pharmaceutical Group pay the last dividend?

The last dividend was paid out on 11/20/2024.

What was the dividend of CSPC Pharmaceutical Group in the year 2023?

In the year 2023, CSPC Pharmaceutical Group distributed 0.2 CNY as dividends.

In which currency does CSPC Pharmaceutical Group pay out the dividend?

The dividends of CSPC Pharmaceutical Group are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von CSPC Pharmaceutical Group

Our stock analysis for CSPC Pharmaceutical Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CSPC Pharmaceutical Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.